7F0 Stock Overview Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Fulgent Genetics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Fulgent Genetics Historical stock prices Current Share Price US$17.60 52 Week High US$26.90 52 Week Low US$15.70 Beta 1.41 1 Month Change 1.15% 3 Month Change -5.38% 1 Year Change -34.57% 3 Year Change -79.48% 5 Year Change 62.96% Change since IPO 70.87%
Recent News & Updates
Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023) Nov 10
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024 Nov 08
New minor risk - Shareholder dilution Nov 03
Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 18
Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023) Aug 04
Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024 Aug 02 See more updates
Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023) Nov 10
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024 Nov 08
New minor risk - Shareholder dilution Nov 03
Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 18
Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023) Aug 04
Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024 Aug 02
Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024 Jul 12
First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023) May 03
Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 12
Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024 Mar 28
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022) Feb 29
Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 14
COO & President recently sold €543k worth of stock Dec 15
New minor risk - Share price stability Nov 06 Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting
Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022) Nov 04
Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023 Oct 18
Chief Financial Officer recently sold €320k worth of stock Sep 01
Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.38 profit in 2Q 2022) Aug 06
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023 Aug 05
Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers Jun 07
First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022) May 07
Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023 May 06
Full year 2022 earnings released: EPS: US$4.77 (vs US$17.25 in FY 2021) Mar 02
Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors Jan 04 Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023
Chief Financial Officer recently sold €62k worth of stock Nov 20
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: EPS: US$0.057 (vs US$4.13 in 3Q 2021) Nov 09
Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million. Nov 09
Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022 Nov 08
Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee Nov 05
The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc Oct 26
Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 21
Less than half of directors are independent Oct 04
Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board Sep 30
Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc Sep 21
Chief Financial Officer recently sold €94k worth of stock Aug 21
Investor sentiment deteriorated over the past week Aug 11
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022 Aug 06
Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021) Aug 05 Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox
Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 20
Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test Jul 06
Chief Financial Officer recently sold €61k worth of stock May 19
First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021) May 05 Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022
Fulgent Genetics, Inc. Announces Executive Appointments May 04 Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022
Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022 Mar 31
Investor sentiment deteriorated over the past week Mar 09
Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022 Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 15
Investor sentiment deteriorated over the past week Jan 22
Investor sentiment deteriorated over the past week Jan 07
Investor sentiment improved over the past week Dec 22
Investor sentiment deteriorated over the past week Dec 06
Chief Operating Officer recently sold €54k worth of stock Dec 02
Chief Operating Officer recently sold €102k worth of stock Nov 19
Investor sentiment improved over the past week Nov 16
Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020) Nov 10
Chief Operating Officer recently sold €99k worth of stock Aug 19
Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020) Aug 10 Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.
Investor sentiment improved over the past week Jul 28 Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 3000E Index
Chief Financial Officer recently sold €75k worth of stock Jun 09
Investor sentiment improved over the past week Jun 09
Chief Operating Officer recently sold €115k worth of stock May 22
First quarter 2021 earnings released: EPS US$6.96 (vs US$0.091 loss in 1Q 2020) May 07
Fulgent Genetics, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021 May 07
Investor sentiment deteriorated over the past week May 05
Investor sentiment deteriorated over the past week Apr 13
Investor sentiment deteriorated over the past week Mar 26
Fulgent Genetics, Inc. Announces Award of Contract from CDC to Study Variants of COVID-19 Virus Mar 17
Chief Operating Officer recently sold €5.4m worth of stock Mar 13
Full year 2020 earnings released: EPS US$9.44 (vs US$0.022 loss in FY 2019) Mar 06
Revenue beats expectations Mar 06
Investor sentiment deteriorated over the past week Mar 05
Fulgent Genetics, Inc. to Report Q4, 2020 Results on Mar 04, 2021 Feb 19
Investor sentiment deteriorated over the past week Feb 18
BioIQ Partners with Fulgent Genetics to Bring Covid-19 Variant Detection to Covid-19 Testing Programs Feb 18
New 90-day high: €107 Feb 04
Investor sentiment improved over the past week Jan 29
Investor sentiment improved over the past week Jan 19
New 90-day high: €63.00 Jan 19
Investor sentiment improved over the past week Jan 05 Shareholder Returns 7F0 DE Healthcare DE Market 7D -1.7% -0.2% -0.3% 1Y -34.6% 16.5% 7.0%
See full shareholder returns
Return vs Market: 7F0 underperformed the German Market which returned 7% over the past year.
Price Volatility Is 7F0's price volatile compared to industry and market? 7F0 volatility 7F0 Average Weekly Movement 6.4% Healthcare Industry Average Movement 4.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7F0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7F0's weekly volatility (6%) has been stable over the past year.
About the Company Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Show more Fulgent Genetics, Inc. Fundamentals Summary How do Fulgent Genetics's earnings and revenue compare to its market cap? 7F0 fundamental statistics Market cap €543.97m Earnings (TTM ) -€158.50m Revenue (TTM ) €266.87m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7F0 income statement (TTM ) Revenue US$277.76m Cost of Revenue US$177.17m Gross Profit US$100.60m Other Expenses US$265.56m Earnings -US$164.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.39 Gross Margin 36.22% Net Profit Margin -59.39% Debt/Equity Ratio 0.3%
How did 7F0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 13:26 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Fulgent Genetics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Karen Koski BTIG Andrew Cooper CGS International Erin Wilson Wright Credit Suisse
Show 3 more analysts 
